If pregn ancy is confirmed, permanently dis continue all study treatment and immediatel y notify BMS Medical Monitor/Study Director or designee (seeSection 9.2.5 ). AE Reporting and Concomitant Medication Assessments Concomitant Medication AssessmentsX Review prior to dosing. Monitor for Non-serious AEsXNon-serious AEs will be collected starting with the first do se of study treatment and through 100 da ys after last dose of study drug, or until new anti-cancer treatment is initiated, whichever com es first. Monitor for SAEs X See note in Table 2-1. Revised Protocol No.: 04 Date: 31-May-2019 26 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e Sample Collection PK Assessments See Table 9.5-1 , Table 9.5-2 , Table 9.5-3, and Table 9.5-4See Section 9.5 . To be performed in all participants. Immunogenicity AssessmentsSee Table 9.5-1, Table 9.5-2, Table 9.5-3, and Table 9.5-4. Revised Protocol No.: 04 Date: 31-May-2019 27 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-2: On-treatment Procedural Outline (CA021002) Procedures for Safety Cohort, and Parts A, B, C, D and Ea,bC1C2 to beyondC2 OnlyC2 OnlyNotes Procedure D1 D2D8 ±±1 daysD15 ±1 daysD22 ±1 daysD1 D2D8 ±1 daysEOT c,d,e Efficacy Assessments Body ImagingEvery 8 weeks (±1 week) prior to dosing at C3 and C5X See Section 9.1 . Brain ImagingFor participants with history of brain metastases, surveillance scans to be done per standard of care frequency, or sooner if clinically indicated.See Section 9.1 .